The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis.

Autor: Rodríguez-Tajes S; Liver Unit, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain.; Consorcio de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, ISCIII, Madrid, Spain., García-Eliz M; Consorcio de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, ISCIII, Madrid, Spain.; Liver Unit, Hospital Universitario y Politécnico de La Fe, Valencia, Spain., Marcos AC; Liver Transplant Unit, Gregorio Marañón Hospital, Madrid, Spain., Campos-Varela I; Liver Unit, Vall d'Hebron University Hospital, Barcelona, Spain., Ros AC; Liver Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain., Loinaz C; Liver Transplant Unit, University Hospital 12 de Octubre, Madrid, Spain., Gómez Bravo MÁ; Liver Unit, Virgen del Rocio Hospital, Sevilla, Spain., Rodríguez-Perálvarez M; Consorcio de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, ISCIII, Madrid, Spain.; Liver Transplant Unit, Hospital Universitario Reina Sofia, Córdoba, Spain., Fabrega E; Liver Unit, Marqués de Valdecilla University Hospital, Santander, Spain., González Diéguez ML; Liver Unit, Hospital Universitario Central de Asturias, Oviedo, Spain., Vinaixa C; Consorcio de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, ISCIII, Madrid, Spain.; Liver Unit, Hospital Universitario y Politécnico de La Fe, Valencia, Spain., Pascasio JM; Consorcio de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, ISCIII, Madrid, Spain.; Liver Unit, Virgen del Rocio Hospital, Sevilla, Spain., Vázquez IF; Liver Transplant Unit, University Hospital 12 de Octubre, Madrid, Spain., Baliellas C; Liver Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain., Castells L; Consorcio de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, ISCIII, Madrid, Spain.; Liver Unit, Vall d'Hebron University Hospital, Barcelona, Spain., Salcedo M; Liver Transplant Unit, Gregorio Marañón Hospital, Madrid, Spain., Prieto M; Consorcio de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, ISCIII, Madrid, Spain.; Liver Unit, Hospital Universitario y Politécnico de La Fe, Valencia, Spain., Crespo G; Liver Unit, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain.; Consorcio de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, ISCIII, Madrid, Spain., Lens S; Liver Unit, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain.; Consorcio de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, ISCIII, Madrid, Spain., Forns X; Liver Unit, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain.; Consorcio de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, ISCIII, Madrid, Spain.
Jazyk: angličtina
Zdroj: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2024 Feb; Vol. 44 (2), pp. 279-285. Date of Electronic Publication: 2023 Dec 15.
DOI: 10.1111/liv.15777
Abstrakt: Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used.
(© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: